Side Area Logo
Welcome to unde omnis iste natus error sit voluptatem accusantium
Keep conected
Overview(2)

INVESTORS

Press Releases

Windtree Therapeutics to Provide AEROSURF® and Business Updates
Conference Call Scheduled for Thursday, January 4, 2018 at 8:00 a.m. Eastern Time
Updated Data on AEROSURF Phase 2a clinical trial in 26-28 week GA infants and Phase 2 Program Summary
2018 Objectives and Expected Deliverables

WARRINGTON, Pa., Dec. 28, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINTD), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a conference call and live webcast at 8:00 AM EST on Thursday, January 4, 2018 to provide updates on the AEROSURF® clinical development program and other business updates including, updated results of the AEROSURF phase 2a clinical trial in premature infants 26 – 28 weeks gestational age and other key AEROSURF development plans and business opportunities currently under consideration that could represent a catalyst for growth in 2018.

To participate in the live call and webcast, and to take part in the question and answer session, dial (844) 802-2436 (domestic) or (412) 317-5129 (international) or visit the investor page of the Company's website at http://windtreetx.investorroom.com/events.

A replay of the conference call will be available one hour after completion of the call through January 11, 2018 and may be accessed by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) by using the referencing conference number 10115385. An archive of the webcast can be accessed on the Company's website at http://windtreetx.investorroom.com/events.

About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases and other potential applications. Windtree's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants and believes that its proprietary technology may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies.

For more information, please visit the Company's website at www.windtreetx.com.

SOURCE Windtree Therapeutics, Inc.

For further information: John Tattory, Senior Vice President and Chief Financial Officer: 215.488.9418 or [email protected]

print email rss